Dr. Cassie Kline discusses the results of the FIREFLY-1 trial at the International Symposium on Pediatric Neuro-Oncology. The phase 2 study focused on treating pediatric low-grade gliomas with tovorafenib to decrease tumor growth velocity, a drug that recently received FDA approval for this specific indication. Dr. Kline is excited about this approval as it is rare to have a pediatric-specific targeted drug. The study was presented at the conference in Philadelphia. Dr. Kline has received grants and clinical trial contracts from various organizations for her work in pediatric neuro-oncology.
Source link
Tovorafenib for low-grade gliomas shows decreased tumor growth in phase 2 study
